Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, October 29, 2015
Bio Products Laboratory, Ltd. (BPL), a manufacturer of plasma-derived therapies, has announced that the U.S. Food and Drug Administration (FDA) has approved Coagadex for the treatment of adults and children (aged 12 years and over) with hereditary ...
read more
Thursday, October 29, 2015
Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) has approved Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes ...
read more
Thursday, October 29, 2015
SNBL USA, Ltd. has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (...
read more
Thursday, October 29, 2015
Capsugel has announced the global commercial launch of its enTRinsicTM drug delivery technology platform.
read more
The collaboration will utilize Affinivax’s proprietary vaccine platform, Multiple Antigen Presentation System (MAPS), to develop vaccines to prevent bacterial nosocomial infections, also referred to as health-care associated infections (HAIs).
read more
Imprimis Pharmaceuticals has announced that it has commenced construction on the company's Allen, Texas compounding pharmacy and plans to register the pharmacy with the U.S. Food and Drug Administration (FDA) as a 503B sterile outsourcing facility ...
read more
Gilead Sciences and WuXi PharmaTech have entered into a strategic partnership to conduct analytical and stability studies of small-molecule new chemical entities to support global marketing applications and commercial products.
read more
Charleston Laboratories and Daiichi Sankyo have announced that a third Phase 3 clinical trial of CL-108, an opioid-containing formulation, met its primary endpoints.
read more
Xcelience is proud to announce the grand opening of its new 71,000 square foot headquarters located at 4910 Savarese Circle in Tampa. The building houses preformulation and formulation development labs and suites, as well as analytical and stability...
read more
Halozyme Therapeutics has announced that the first healthy subject has been dosed in a Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of a subcutaneous formulation of rivipansel, a compound discovered by GlycoMimetics...
read more
The Novartis Foundation and its partners have begun screening patients in the Community-based Hypertension Improvement Project (ComHIP), a two-year program designed to evaluate the impact of an innovative healthcare model on hypertension management ...
read more
Monday, November 02, 2015
CluePoints today announced a strategic collaboration with clinical trials business solutions consultancy, Widler & Schiemann Ltd. The collaboration will bring together CluePoints' award-winning RBM software with Widler & Schiemann's risk-assessment ...
read more
Tuesday, November 03, 2015
Cytovance Biologics, Inc. announced that it has entered into a Development and Manufacturing Agreement for the production of Phase III batches of a universal flu vaccine, M-001, with BiondVax Pharmaceuticals Ltd. (TASE: BVXV) (NASDAQ: BVXV), a ...
read more
Tuesday, November 03, 2015
PharPoint Research, Inc., a contract research organization (CRO), has announced that the stable growth of new employees has led to the expansion of their Wilmington, NC office.
read more
Tuesday, November 03, 2015
Moberg Pharma AB has announced that Moberg Pharma and Colep have entered a Development Agreement for MOB-015 – a novel topical formulation of terbinafine for onychomycosis (nail fungus).
read more